Day: March 8, 2023

Posted on

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Nyxoah to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – March 7, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 33rd Annual Healthcare Conference, which takes place March 13-15, 2023, virtually.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update on Tuesday, March 14, 2023, at 11:20am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000796826

Posted on

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder

Agreement follows STALICLA’s recent in-licencing of mavoglurant from Novartis

Geneva, Switzerland – 8 March 2023, STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). The agreement covers the clinical development program of mavoglurant to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

NIDA is the lead federal agency supporting scientific research on drug use and addiction to improve individual and public health. Under the terms of the CRADA, NIDA will cover under its own account the Phase 3 trial for mavoglurant, which is slated to enrol up to 330 patients. The investigational product was in-licensed by STALICLA from Novartis in return for undisclosed late-stage milestone payments and royalties, in an agreement announced in January this year. Novartis has also taken an equity stake in STALICLA.

Lynn Durham, STALICLA’s Founder & CEO, commented: “Our CRADA with NIDA allows us to enter into late stage development and is a testament to STALICLA’s commitment to bring new treatments to patients suffering from neuropsychiatric and neurodevelopmental disorders. It is also a validation of mavoglurant’s potential in treating patients with substance-abuse disorders. We have onboarded an exceptional partner in NIDA and we are excited about working together to accelerate mavoglurant towards a new drug application.”

About mavoglurant

Mavoglurant is the most clinically advanced selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist. mGluR5 has been tied to mood disorders, addiction as well as rare and common forms of Autism. In clinical Phase 2 studies, mavoglurant has been shown to induce abstinence in cocaine use disorder patients through inhibition of mGluR5, with no evidence of withdrawal liability.

About STALICLA

STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.

STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.

With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.

The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.

STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

Contacts

STALICLA SA
Lynn Durham, CEO
Lynn.durham@stalicla.com		 Media enquiries
Consilium Strategic Communications
stalicla@consilium-comms.com

GlobeNewswire Distribution ID 1000796906

 

Posted on

Cambodia, Laos to Foster Collaboration Along Common Border

Cambodia and Laos are committed to continuing intimate bilateral cooperation to maintain peace, stability, economic growth, and harmony between the two peoples, particularly those along the shared border.
The commitment was made in a farewell meeting between H.E. Kim Rithy, Governor of Preah Vihear province and H.E. Khomsone Khounpaseuth, outgoing Consul General of the Lao People’s Democratic Republic to Stung Treng province at Preah Vihear province on Mar. 7.
H.E. Kim Rithy spoke highly of the friendship, solidarity, and good cooperation in all sectors between the two nations, especially between the two peoples along the Cambodian-Lao border.
H.E. Khomsone Khounpaseuth lauded Cambodia’s rapid development in all domains, including Preah Vihear province.
He pledged to contribute to boosting the relations and cooperation between both countries after his tenure as the Lao Consul General to Stung Treng.

Source: Agence Kampuchea Presse

Posted on

China Recommits More Financing for Cambodia’s Demining

The People’s Republic of China has committed US$13.2 million for the China-Aided Cambodia Landmine Elimination Project Phase III (CCL-III) 2023-2025.
The commitment was highlighted in a press release issued by Cambodian Mine Action Centre (CMAC) on Mar. 7.
The additional financial assistance from PRC followed remarkable outcomes of the China-Aided Cambodia Landmines Elimination Project phases I and II (CCL-I-II) from 2018 to 2022 that freed 74,922,784 square metres of land in Cambodia from mines, added the release.
Of the cleared land, 2,916,419 square metres have been used for agricultural activities and 54,564,739 square metres were allocated for the construction of schools, hospitals, pagodas, bridges, roads, and other infrastructures.
After all, the CCL-I-II worth about US$10 million have contributed to community development and bettered livelihood of 674,618 people in the provinces, Kampong Thom, Siem Reap, Preah Vihear, Stung Treng, Kampong Chhnang, Svay Rieng, Oddar Meanchey, and Kratie.
Building on the first two phases, the CCL-III affective from March 2023 will free more land in Cambodia from mines, contributing significantly to the country’s commitment to achieve land-mine free status by 2025.

Source: Agence Kampuchea Presse

Posted on

PM Urges for Attention to Original Form of National Culture

Prime Minister Samdech Akka Moha Sena Padei Techo Hun Sen has called for attention to maintaining the original form of the national culture to avoid long-term impact.
The Premier made the appeal in a voice message this morning, after a disagreement between the Ministry of Culture and Fine Arts (MOCFA) and Mrs. Try Dana, a famous online jewelry seller, went viral on social media network in the past few days.
Mrs. Try Dana blamed the MOCFA of being too strict to her request to take promotional photos at Angkor during the forthcoming Angkor Sankranta in Siem Reap, while the MOCFA rejected the blame, explaining that the ministry required some changes to make sure that the dresses and decorations are conform with the original form to avoid public criticism and in favour of the next generations.
“Showcasing the Khmer culture is good, but if it does not follow the original form, it is tantamount to cultural destruction,” stressed Samdech Techo Hun Sen in the voice message.
Mrs. Try Dana should not blame MOCFA, it is the ministry’s obligation to protect the national culture, if not it will be accountable for its mistakes to the Royal Government and the National Assembly, he added.
The Prime Minister said the explanation of the MOCFA is right because cultural representations that are different from the original would not only affect our culture, but we could also be accused by neighbouring countries of copying their culture.
Samdech Techo Hun Sen thus asked Mrs. Try Dana to cooperate with the MOCFA while the latter can dispatch specialists to assist the former if requested for the success of her cultural promotion plan.

Source: Agence Kampuchea Presse

Proudly powered by WordPress